STOCK TITAN
  1. Home
  2. News
  3. APTOF

Aptose Bioscienc (APTOF) Stock News

APTOF OTC

Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTOF), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.

Aptose Biosciences Inc. (APTOF) is a clinical-stage precision oncology company focused on developing small molecule therapies for hematologic cancers, particularly acute myeloid leukemia (AML). The news flow around Aptose centers on the clinical progress of its lead oral kinase inhibitor tuspetinib (TUS), corporate financing arrangements, and a planned acquisition by Hanmi Pharmaceutical Co. Ltd.

Investors following APTOF news will see regular updates on the TUSCANY Phase 1/2 trial, where tuspetinib is combined with standard dosing of venetoclax and azacitidine (TUS+VEN+AZA) as a triple drug frontline therapy for newly diagnosed AML patients ineligible for induction chemotherapy. Company press releases highlight safety data, complete remission (CR/CRh) rates, minimal residual disease (MRD) negativity, and responses across diverse genetic subtypes, including patients with adverse mutations such as TP53, RAS, FLT3-ITD, NPM1c, and myelodysplasia-related mutations.

The Aptose news stream also includes quarterly financial results, where management discusses research and development spending by program, cash position, and reliance on loan facilities from Hanmi to fund operations. Additional items include announcements of conference presentations at major meetings such as the European Hematology Association (EHA), the European School of Haematology (ESH), and the American Society of Hematology (ASH), where new clinical data from TUSCANY are presented.

Another key category of news involves transaction and governance updates. Aptose has announced an arrangement agreement under which a Hanmi subsidiary will acquire all outstanding common shares not already owned or controlled by Hanmi or its affiliates, subject to shareholder and court approvals. The company also reports outcomes of shareholder meetings and changes in its independent auditor. For readers tracking APTOF, this news page provides a consolidated view of clinical, financial, and corporate developments disclosed by the company.

News

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

Rhea-AI Summary
Aptose Biosciences has secured a new loan agreement with Hanmi Pharmaceutical for up to US$8.5 million to advance the development of tuspetinib (TUS) in triple drug therapy for acute myeloid leukemia (AML). The loan will support the ongoing TUSCANY Phase 1/2 clinical trial, which combines TUS with azacitidine and venetoclax for newly diagnosed AML patients ineligible for induction chemotherapy. Tuspetinib is an oral medication targeting multiple kinases including SYK, FLT3, KIT, JAK1/2, and RSK2. Early trial data from initial cohorts has shown promising results with complete responses and minimal residual disease negativity across patients with various mutations, while maintaining a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
none
-
News

Aptose Provides Corporate Updates

Rhea-AI Summary
Aptose Biosciences, a clinical-stage precision oncology company, has secured a short-term cash advance from CEO Dr. William G. Rice to cover immediate obligations including payroll and continue development of tuspetinib, their oral kinase inhibitor. The advance is non-interest bearing, unsecured, and repayable without penalty. Despite this funding, Aptose warns it may face insolvency proceedings without additional funding in the coming days. The company also announced the resignation of board member Carol Ashe, effective June 16, 2025. The cash advance constitutes a related-party transaction under MI 61-101, though Aptose is exempt from formal valuation and minority shareholder approval requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.52%
Tags
none
-
News

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Rhea-AI Summary
Aptose Biosciences presented promising clinical data from its TUSCANY Phase 1/2 trial evaluating tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed AML patients. The study included 10 patients across three dosage cohorts (40mg, 80mg, 120mg). In the 40mg cohort, three patients achieved complete remissions with MRD-negativity. The 80mg cohort showed 100% composite complete remissions, while the 120mg cohort patients remain under treatment. Notably, the treatment demonstrated efficacy across diverse genetic populations, including challenging cases with TP53 mutations. The triplet therapy showed favorable safety with no dose-limiting toxicities, no treatment-related deaths, and all patients remaining alive. The trial continues at 10 leading U.S. clinical sites with expected enrollment of 18-24 patients by mid-late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
clinical trial
News

Aptose Announces Results from Annual and Special Meeting of Shareholders

Rhea-AI Summary
Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, held its annual and special meeting on May 27, 2025, with 57.90% shareholder participation. All nominated directors were successfully re-elected with strong approval ratings above 97%. Shareholders approved key proposals including: an advisory resolution on executive compensation, amendments to the 2021 stock incentive plan, and a potential reverse stock split at a ratio between 1-for-2 to 1-for-20. The meeting was adjourned to allow time to find a successor auditor to KPMG LLP. The company is developing a tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
-
News

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

Rhea-AI Summary
Aptose Biosciences has announced significant progress in its Phase 1/2 TUSCANY trial, evaluating tuspetinib (TUS) in combination with venetoclax and azacitidine for newly diagnosed AML patients. The Cohort Safety Review Committee (CSRC) has approved dose escalation from 80mg to 120mg of TUS following positive safety and efficacy data from initial cohorts. The trial has shown complete remissions (CRs) and minimal residual disease (MRD)-negativity across diverse mutations, with no significant safety concerns or dose-limiting toxicities. Notably, the treatment demonstrated effectiveness in difficult-to-treat populations, including patients with TP53 and RAS mutations. The TUSCANY trial, conducted at 10 leading U.S. clinical sites, aims to enroll 18-24 patients by mid-late 2025. Updated data will be presented at the European Hematology Association Congress in June 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
clinical trial
-
News

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Rhea-AI Summary
Aptose Biosciences (OTC: APTOF) has been selected to present data from its TUSCANY Phase 1/2 clinical trial at the EHA Congress 2025 in Milan. The trial evaluates tuspetinib (TUS) in combination with venetoclax and azacitidine as a triplet therapy for newly diagnosed AML patients ineligible for chemotherapy. Initial results from the 40mg and 80mg dose cohorts have shown promising outcomes, including safety, complete remissions, and MRD negativity across diverse mutations, particularly in TP53-mutated/CK AML and FLT3-wildtype AML patients. The study is ongoing at 10 leading U.S. clinical sites, with expected enrollment of 18-24 patients by mid-late 2025. The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy for treating diverse populations of newly diagnosed AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
clinical trial
News

Aptose Reports First Quarter 2025 Results

Rhea-AI Summary
Aptose Biosciences reported Q1 2025 financial results and progress in its TUSCANY clinical trial for tuspetinib (TUS) in combination with venetoclax and azacitidine for frontline AML treatment. The trial showed promising results with 6 out of 7 patients achieving complete remissions across two dose cohorts (40mg and 80mg). Notably, two patients with TP53 mutations showed positive responses. The company reported a reduced net loss of $5.5M compared to $9.6M in Q1 2024, with cash reserves of $4.7M as of March 31, 2025. However, current funding only supports operations until end of May 2025. Aptose was delisted from Nasdaq in April 2025 and now trades on OTC Markets (APTOF) and TSX (APS). Research and development expenses decreased to $2.3M from $6.4M year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
earnings

FAQ

What is the current stock price of Aptose Bioscienc (APTOF)?

The current stock price of Aptose Bioscienc (APTOF) is $1.5801 as of June 2, 2026.

What is the market cap of Aptose Bioscienc (APTOF)?

The market cap of Aptose Bioscienc (APTOF) is approximately 4.0M.